Latest Period
Q4 2025
- Info
- Insider Trading
- Financials
- Holders: LYEL, LYEL
Security Snapshot
Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 (LYEL) Institutional Ownership
CUSIP: 55083R203
13F Institutional Holders and Ownership History from Q2 2025 to Q1 2026
Institutions Reporting
67
Shares (Excl. Options)
11,405,527
Price
$30.78
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, par value $0.0001
- Symbol
- LYEL on Nasdaq
- Shares outstanding
- 19,139,684
- Price per share
- $20.06
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 11,405,527
- Total reported value
- $350,313,783
- % of total 13F portfolios
- 0%
- Share change
- +239,937
- Value change
- +$8,387,255
- Number of holders
- 67
- Price from insider filings
- $20.06
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- LYEL - Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 is tracked under CUSIP 55083R203.
- 67 institutions reported positions in Q4 2025.
- 5 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 67 to 3 between Q4 2025 and Q1 2026.
- Reported value moved from $350,313,783 to $23,129.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 67 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 55083R203?
CUSIP 55083R203 identifies LYEL - Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 55083R203:
Significant Owners of Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 (LYEL) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ARCH Venture Fund IX, L.P. | 13% | $44,807,053 | 2,759,072 | ARCH Venture Fund IX, L.P. | 30 Sep 2025 | |||
| Innovative Cellular Therapeutics Holdings Ltd | 9.8% | $30,855,810 | 1,900,000 | Innovative Cellular Therapeutics Holdings Ltd | 06 Nov 2025 | |||
| Foresite Capital Fund IV, L.P. | 7.6% | $23,622,818 | 1,454,616 | James B. Tananbaum | 30 Sep 2025 | |||
| Gates Frontier, LLC | 5.6% | $10,628,242 | 1,040,964 | Gates Frontier, LLC | 25 Jul 2025 | |||
| NEWTON (PTC) Ltd | 3.9% | $12,256,220 | 754,698 | Newton (PTC) Limited | 30 Sep 2025 |
As of 31 Dec 2025, 67 institutional investors reported holding 11,405,527 shares of Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 (LYEL). This represents 60% of the company’s total 19,139,684 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 (LYEL) together control 58% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| ARCH Venture Management, LLC | 14% | 2,759,072 | 0% | 13% | $84,924,236 |
| GSK plc | 7.9% | 1,512,659 | 0% | 5.8% | $46,559,644 |
| MWG Caph Ltd | 5.3% | 1,008,116 | 0% | 43% | $31,029,810 |
| VANGUARD GROUP INC | 4.3% | 826,430 | +6.1% | 0% | $25,437,516 |
| Foresite Capital Management IV, LLC | 4.2% | 800,399 | 0% | 11% | $24,636,281 |
| Orland Properties Ltd | 3.9% | 754,698 | 0% | 4.3% | $23,229,604 |
| Almitas Capital LLC | 3% | 577,807 | 0% | 3.9% | $17,784,899 |
| Foresite Capital Management V, LLC | 2.5% | 477,078 | 0% | 8.9% | $14,684,461 |
| venBio Partners LLC | 1.8% | 337,697 | -29% | 4.8% | $10,394,314 |
| CITADEL ADVISORS LLC | 1.7% | 324,701 | -4.4% | 0.01% | $9,994,297 |
| Alphabet Inc. | 1.5% | 293,256 | 0% | 0.35% | $9,026,420 |
| BlackRock, Inc. | 0.95% | 181,837 | +2.8% | 0% | $5,596,944 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.85% | 162,997 | +25% | 0% | $5,019,879 |
| HSG Holding Ltd | 0.8% | 152,299 | 0% | 0.24% | $3,935,406 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.79% | 151,016 | +835% | 0.01% | $4,648,272 |
| Invesco Ltd. | 0.52% | 98,649 | 0% | $3,036,416 | |
| GOLDMAN SACHS GROUP INC | 0.51% | 96,675 | 0% | $2,975,657 | |
| MIC Capital Management UK LLP | 0.45% | 87,028 | 0% | 0.61% | $2,678,722 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.45% | 85,423 | +7.4% | 0% | $2,629,320 |
| RBF Capital, LLC | 0.39% | 74,585 | -22% | 0.1% | $2,295,726 |
| MARSHALL WACE, LLP | 0.38% | 73,315 | 0% | $2,256,635 | |
| MILLENNIUM MANAGEMENT LLC | 0.31% | 58,651 | -53% | 0% | $1,805,278 |
| JOHNSON & JOHNSON | 0.29% | 54,887 | 0% | 0.3% | $1,689,422 |
| STATE STREET CORP | 0.27% | 51,472 | +53% | 0% | $1,584,308 |
| MORGAN STANLEY | 0.22% | 42,949 | +16% | 0% | $1,321,971 |